How to get insurance to cover GLP-1 compounding (after the FDA enforcement wave)?

In October 2024 and again in March 2026, FDA actions ended the shortage-list authority that had allowed 503A compounding pharmacies and 503B outsourcing facilities to compound semaglutide, tirzepatide, and related GLP-1 products at scale. The enforcement actions, combined with mounting plaintiff-bar interest in adverse events from compounded GLP-1, materially changed the carrier appetite landscape.

Most generalist druggist professional liability and pharmacy products liability carriers added GLP-1 exclusions or sublimits at renewal in 2024-2026. Some carriers exited GLP-1 compounding underwriting entirely. The remaining market is a narrow specialty panel that prices the exposure explicitly rather than absorbing it inside the broader compounding pharmacy program.

Carriers still willing to underwrite GLP-1 compounding typically require: written dose protocols specifying maximum dose, titration schedules, and contraindications; prescriber credentialing documentation showing licensed physician / NP / PA oversight; USP 797 sterile compounding compliance evidence (and USP 800 for hazardous-drug handling where applicable); adverse-event reporting workflows; documented patient screening (history of pancreatitis, gallbladder disease, thyroid C-cell tumors); informed consent processes; and good-faith physician-patient relationship documentation.

Operators that can produce these documents in the application typically bind at terms that are workable, if more expensive than pre-2024 GLP-1 pricing. Operators without these workflows are typically declined or quoted at materially uncompetitive terms.

Specialty market GLP-1 endorsements typically add $5,000-$30,000+ to the base druggist professional liability and products liability premium depending on the volume of GLP-1 prescriptions per month and the size of the GLP-1 revenue line as a share of total revenue. The 503B market for GLP-1 has narrower carrier appetite than 503A and prices materially higher.

Some operators structure GLP-1 compounding in a separately named insured entity (separate LLC) so the GLP-1 exposure does not erode the limits on the broader compounding pharmacy program. Whether this structure is appropriate depends on revenue mix and contractual relationships - operators considering it should coordinate with both their broker and counsel.

For operators already carrying GLP-1 revenue, the program review should happen 90+ days before renewal. The steps: (1) confirm whether the current carrier intends to renew GLP-1 coverage and at what terms; (2) market the program to the specialty GLP-1 carrier panel if the current carrier exits or restricts; (3) review and document the compliance and operational workflows the specialty market expects; (4) coordinate with hospital purchase contract and PBM credentialing obligations if applicable; (5) bind 30+ days before renewal to allow for COI updates to downstream contracts.